People living with type 2 diabetes carry a heavier cancer burden than those without the condition, and that burden has been growing heavier over the past quarter-century. That is the conclusion of a nationwide Danish study presented at the annual meeting of the European Association for the Study of Diabetes (EASD), held in Milan, Italy, from Sept. 28 to Oct. 2.
The research, led by Dr. Tinne Laurberg of the Steno Diabetes Center Aarhus at Aarhus University Hospital in Denmark, drew on nationwide health registries covering the country's entire adult population — a scale that gives the findings unusual weight for a question that has historically lacked robust, population-level evidence.
A Quarter-Century of Registry Data
To trace how cancer patterns have shifted, the researchers compared the occurrence of newly diagnosed cancers among Danish adults aged 18 and older with and without type 2 diabetes between 1996 and 2022. The analysis separated obesity-related cancers from those not linked to obesity, allowing the team to test whether the widening gap was being driven by a specific subset of malignancies.
That distinction turned out to matter a great deal. The divergence between people with and without type 2 diabetes was largely explained by cancers associated with obesity — a category that includes colorectal cancer and postmenopausal breast cancer, among others.
The Numbers Behind the Widening Gap
The study's headline figures show a consistent disadvantage for people with type 2 diabetes, and one that has become more pronounced over time.
During the most recent period examined, spanning 2010 to 2022, overall cancer incidence was 12% higher among men with type 2 diabetes and 22% higher among women with type 2 diabetes compared with adults without diabetes. In the earlier window, from 1996 to 2009, those gaps were narrower: 9% for men and 15% for women.
In other words, the excess cancer risk faced by people with type 2 diabetes did not merely persist across the study period — it grew. The increase was more striking in women than in men in both eras, though the trend moved in the same direction for both sexes.
Why Obesity-Related Cancers Stand Out
The concentration of the trend within obesity-related cancers points toward shared underlying biology rather than coincidence. Obesity is a well-established risk factor for type 2 diabetes and for several cancer types, and the two conditions frequently coexist in the same patients.
That overlap means the rising cancer incidence documented in the study likely reflects, at least in part, the parallel rise in excess body weight across high-income populations. But the researchers' framing suggests the diabetes diagnosis itself is not merely a marker of shared risk — it may be an independent contributor as well.
How Diabetes May Influence Cancer Development
The study's background notes outline several mechanisms that could connect type 2 diabetes to cancer initiation and progression. Prolonged exposure to elevated blood sugar and insulin levels may play a role, as may insulin resistance and the chronic, low-grade inflammation that accompanies metabolic disease.
These pathways are not mutually exclusive. A person with long-standing type 2 diabetes may simultaneously experience sustained hyperglycemia, compensatory hyperinsulinemia, impaired insulin signaling, and persistent inflammatory signaling — a combination that could create conditions favorable to uncontrolled cell growth over many years.
The long latency of cancer development also helps explain why the gap has widened gradually rather than appearing abruptly. Registry data stretching back to 1996 captures a population whose metabolic exposures accumulated decade by decade.
Cancer Now a Leading Cause of Death in Type 2 Diabetes
The stakes of these findings have shifted dramatically. Over the past decade, cancer has become the leading cause of death among people with type 2 diabetes in Denmark and other high-income countries.
That represents a notable change in the clinical landscape. For decades, cardiovascular complications dominated the conversation around diabetes mortality. As cardiovascular care for people with diabetes has improved, cancer has moved into the position of greatest relative threat — making it essential to understand how the incidence of specific cancer types has changed over time, and whether people with diabetes are being reached by existing prevention infrastructure.
Yet despite the importance of the question, long-term, population-level data comparing cancer incidence trends in people with and without type 2 diabetes have been scarce. The Danish registries offer an unusually complete picture because they capture a defined national population over an extended period rather than relying on survey samples or single-institution records.
What Researchers Say Should Happen Next
Laurberg framed the results as a call to integrate cancer prevention more firmly into diabetes care, rather than treating the two conditions as separate clinical concerns.
Describing the findings, she said they underscore the growing cancer burden among people with type 2 diabetes and highlight the need to prioritize cancer prevention and early detection as part of long-term diabetes care.
She placed particular emphasis on common obesity-related cancers — colorectal and postmenopausal breast cancer — for which screening programs already exist in many countries. The concern, she suggested, is not the absence of screening infrastructure but whether people with type 2 diabetes are participating in it fully. Encouraging greater uptake of established programs could be one of the most direct ways to close the gap.
That framing positions the study less as a warning about an untreatable risk and more as an argument for better use of tools that already exist. If people with type 2 diabetes face a 12% to 22% higher cancer incidence, ensuring they are not underrepresented in screening populations becomes a concrete, actionable priority.
Key Takeaways
- Cancer incidence was 12% higher in men and 22% higher in women with type 2 diabetes than in adults without diabetes during 2010–2022.
- The equivalent gaps in 1996–2009 were 9% for men and 15% for women, meaning the disparity has widened.
- The trend was largely driven by obesity-related cancers, including colorectal and postmenopausal breast cancer.
- Cancer has become the leading cause of death among people with type 2 diabetes in Denmark and other high-income countries.
- Researchers recommend embedding cancer prevention and early detection into routine long-term diabetes care, with greater participation in existing screening programs.
The Broader Picture
Because the analysis covers an entire national adult population across 27 years, its findings carry implications beyond Denmark's borders. Other high-income countries with similar patterns of rising obesity, aging populations, and improving cardiovascular outcomes in diabetes are likely to face comparable — or converging — trends.
The study also reframes what a type 2 diabetes diagnosis signals over the long term. Alongside the well-known risks of heart, kidney, and nerve complications, cancer now belongs on the list of conditions that clinicians and patients should be actively monitoring for. The message from Aarhus is that prevention and early detection, embedded in the routine care people with diabetes already receive, may offer the most practical route to narrowing a gap that has been widening for a generation.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
